INSM
INSMED Inc
Nasdaq: INSM · Bridgewater, NJ · Healthcare
$93.39-1.67 (-1.76%)Closed
Market Cap$20.39B
Cash$1.16Bmost recent
Runway16 mo$222.7M Q burn
P/E (TTM)—EPS $-6.42
52-Wk Range$91.88 – $211.41
Avg Volume3.0M3-month
Price & Trading Activity
Daily close with catalyst overlays and trading volume
$93.39+30.2%
Pipeline
Drug candidates sponsored by INSMED · ClinicalTrials.gov
| Phase | Drug / Candidate | Indications | Status | Next Completion | Trials | |
|---|---|---|---|---|---|---|
| Phase 2 | rhIGF-I/rhIGFBP-3 | Growth Hormone Insensitivity Syndrome (GHIS)+2 more | Completed | 2008-12-29past | 2 | |
| Phase 3 | Liposomal amikacin for inhalation (Arikayce™) using the PARI Investigational eFlow® Nebulizer. | Pseudomonas Aeruginosa Infection | Completed | 2013-06past | 1 | |
| Phase 3 | Liposomal amikacin for inhalation | Cystic Fibrosis+1 more | Completed | 2015-07-16past | 3 | |
| Phase 3 | LAI (Liposomal Amikacin for Inhalation) 590 mg | Mycobacterium Infections, Nontuberculous | Completed | 2018-07-03past | 1 | |
| Phase 3 | LAI 590 mg | NTM Lung Infection Due to MAC | Completed | 2018-10-17past | 1 | |
| Phase 3 | Brensocatib 10 mg | Non-Cystic Fibrosis Bronchiectasis | Completed | 2024-10-28past | 2 | |
| Phase 3 | ALIS | Mycobacterium Infections, Nontuberculous | Completed | 2025-11-21past | 2 | |
| Phase 2 | Treprostinil Palmitil | Pulmonary Arterial Hypertension+2 more | Active, not recruiting | 2026-12-31 | 5 | |
| Phase 2 | Treprostinil Palmitil Inhalation Powder | Pulmonary Hypertension+5 more | Recruiting | 2027-02-07 | 7 | |
| Phase 1 | ARIKACE™ | Cystic Fibrosis | Completed | 2008-02-27past | 1 | |
| Phase 1 | Cisplatin liposomal | Osteosarcoma Metastatic | Completed | 2008-03past | 1 | |
| Phase 2 | 280 mg Arikayce™ | Bronchiectasis | Completed | 2009-05-11past | 1 | |
| Phase 1 | Arikayce™ 560 mg | Cystic Fibrosis | Completed | 2009-06past | 1 | |
| Phase 2 | Arikayce™ | Cystic Fibrosis | Completed | 2010-11-02past | 1 | |
| Phase 2 | Liposomal amikacin for inhalation (LAI) | Mycobacterium Infections, Nontuberculous | Completed | 2014-08-18past | 1 | |
| Phase 2 | OpSCF | Atopic Dermatitis | Completed | 2024-09-03past | 1 | |
| Phase 2 | Brensocatib | Cystic Fibrosis+7 more | Not yet recruiting | 2026-11-25 | 11 | |
| Phase 2 | rhIGF-1/rhIGFBP-3 | Noonan Syndrome | Terminated | — | 1 | |
| Phase 1 | SLIT™ Amikacin | Cystic Fibrosis | Completed | 2005-02-08past | 1 | |
| Phase 1 | C16TR | Healthy Volunteers | Completed | 2015-12-18past | 1 | |
| Phase 1 | INS1007 | Healthy Volunteers | Completed | 2019-08-01past | 1 | |
| Phase 1 | [14C]-brensocatib | Healthy Volunteers | Completed | 2021-09-14past | 1 | |
| Phase 1 | Brensocatib Oral Solution | Healthy Participants | Completed | 2024-05-24past | 1 | |
| Phase 1 | TPIP F2 | Healthy Volunteers | Completed | 2025-10-25past | 1 | |
| Phase 1 | INS1033 | Healthy Volunteers | Recruiting | 2027-03-22 | 1 | |
| Phase 1 | INS1201 | Duchenne Muscular Dystrophy | Active, not recruiting | 2028-01-31 | 1 | |
| Phase 1 | INS1202 | Amyotrophic Lateral Sclerosis | Recruiting | 2030-03-31 | 1 |
Valuation
Risk-adjusted NPV
Loading pipeline…
Peer comparison
Cohort check
No peer cohort defined for INSM. Cohorts currently cover gene editing, mRNA, rare-disease gene therapy, and large-cap biotech — more coming soon.